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Studies have shown an association between recurrent pregnancy loss and inherited thrombophilia in Caucasian populations, but
there is insuﬃcient knowledge concerning triethnic populations such as the Colombian. The aim of this study was to evaluate
whether inherited thrombophilia is associated with recurrent pregnancy loss. Methods. We conducted a case-control study of 93
patients with recurrent pregnancy loss (cases) and 206 healthy multiparous women (controls) in a Colombian subpopulation.
Three single nucleotide polymorphisms (SNPs) markers of the inherited thrombophilias factor V Leiden, prothrombin G20210A,
and methylenetetrahydrofolate reductase C677T were genotyped by PCR-RFLP. Activated protein C resistance and plasma levels
of antithrombin, protein C, and protein S were also measured. Results. The frequency of thrombophilia-associated SNPs, activated
protein C resistance, and anticoagulant protein deﬁciencies, was low overall, except for the methylenetetrahydrofolate reductase
C677T SNP. The diﬀerences between patients and controls had no statistical signiﬁcance. Conclusion. Our study conﬁrms the low
prevalence of inherited thrombophilias in non-Caucasian populations and it is unlikely that the tested thrombophilias play a role
in the pathogenesis of recurrent pregnancy loss in this Colombian population.
1.Introduction
Pregnancy is an acquired hypercoagulable state and women
with a prior tendency to thrombosis may develop clini-
cal symptoms of placental vascular complications such as
preeclampsia,intrauterinegrowthrestriction,andfetaldeath
for unknown causes, that impact the maternal-fetal mor-
bidity and mortality [1–4]. Recurrent pregnancy loss is an
important obstetric complication with a prevalence of 1–
5% [5]. Inherited thrombophilia has been postulated as a
cause of recurrent pregnancy loss, although the association
between inherited thrombophilia and recurrent pregnancy
loss has not been conclusively established. Some studies have
demonstrated an association between recurrent pregnancy
loss and prothrombotic states rendered by some genetic
single nucleotide polymorphisms (SNPs), such as factor V
Leiden G1691A (FV Leiden), prothrombin G20210A (FII
G20210A), and methylenetetrahydrofolate reductase C677T
(MTHFR C677T), and activated protein C resistance (APC
resistance) [6–14], whereas others have reported lack of any
association[15–19].Inaddition,aretrospectivecohortstudy
showed that women with deﬁciencies of antithrombin (AT),
protein C (PC), or protein S (PS) have an eightfold increased
relative risk of thrombosis during pregnancy compared to
controls [20].
Most of the studies on thrombophilia and recurrent
pregnancy loss have been conducted in Caucasian popu-
lations [21, 22]. Therefore, the association between these2 Thrombosis
thrombophilias and recurrent pregnancy loss is almost
unknown in triethnic populations such as the Colombian
population whose genetic mixture is approximately 70%
Caucasian, 15% Amerindian, and 15% African [23, 24]. We
conducted this study to evaluate the association between
inherited thrombophilia and recurrent pregnancy loss in a
group of patients from Colombia.
2. Patientsand Methods
2.1. Study Population. An unmatched case-control study was
conducted on 93 patients and 206 healthy women from
a province in Northwest Colombia (Antioquia) chosen for
convenience. The inclusion criteria for the patient group
were a history for recurrent pregnancy loss (three or more
miscarriages) and any of the following vascular pregnancy
manifestations: one or more second-trimester or later loss-
es, severe or recurrent preeclampsia, intrauterine growth
restriction, placental abruption, or otherwise unexplained
intrauterine death. The women with recurrent pregnancy
loss were selected among more than 3000 patients who had
consulted, over the last 20 years, to the Reproduction Group
at Universidad de Antioquia in Medell´ ın, Colombia. The
control group included 206 healthy women with a history
of two or more normal pregnancies, no more than one
miscarriage,andnohistoryofanyofthecriteriaforinclusion
in the patient group. The sample size estimated for a type
I error of 5% and a power of 80% was 300 subjects (2:1
ratio between controls and cases). This estimation was based
on the following average ratios of SNPs in healthy European
populations and their odds ratio for recurrent pregnancy
loss: 4.3% of heterozygous FV Leiden with an odds ratio
(OR) of 4 [8, 25, 26]; 3% of FII G20210A with OR of 3.7
[8, 26]; 9% of MTHFR C677T with an OR of 3.1 [26–
28].Europeanpopulationswereselectedasreferencebecause
insuﬃcient information was available about the frequency of
inherited thrombophilia in a population with mixed genetic
ancestry such as the Colombian. Additionally, deﬁciencies of
AT, PC, and PS were determined in an exploratory manner,
as a pilot study, since the sample size was not powered to
discriminate diﬀerences between patients and controls. This
study was approved by the Ethics Committee of the Medical
Research Center at the Universidad de Antioquia and all
subjects provided informed consent.
2.2. Thrombophilia Screening. Blood samples were drawn
from women who were not taking any anticoagulant drugs
and who were at least 3 months past the last obstetric event
to prevent changes in the APC resistance status and plasma
levels of coagulation proteins.
Thrombophilia-associated SNPs were genotyped using
the methods described by Ridker et al. [29]( F VL e i d e n ) ,
P o o r te ta l .[ 30] (FII G20210A), and Mandel et al. [31]
(MTHFRC677T).TheAPCresistancestatuswasdetermined
in plasma using a second-generation functional assay based
on activated partial thromboplastin time with factor-V-
deﬁcient plasma (Test APC RESISTANCE V, Instrumenta-
tionLaboratory,Lexington,MA,USA)consideringapositive
Table 1: Characteristics of patients and controls.
Characteristics Cases
(n = 93)
Controls
(n = 206)
Age, mean ± SD (years) 34.1±0.94 1 .6 ±0.7
Age, range (years) 18–79 23–83
Number of previous pregnancies,
mean ± SD 4.4 ±1.92 .8 ±1.3
Number of pregnancy losses, mean ± SD 3.8 ±1.40 .1 ±0.3
Family history of venous thrombosis (%) 25.8 29
Medical history of venous thrombosis (%) 6.5 0
History of severe or recurrent
preeclampsia (%) 13.0 0
History of pregnancies with intrauterine
growth restriction (%) 1,9 0
History of placental abruption (%) 0.9 0
SD: standard deviation; n:n u m b e ro fw o m e n
APC resistance when the ratio a/b was lower than 2 being
(a) in the presence, and (b) in the absence of activated PC.
The activities of AT, PC, and PS were determined with com-
mercial kits (IL Test Antithrombin, IL Test ProClot, and IL
Test Protein S, resp.; Instrumentation Laboratory, Lexington,
MA, USA). These proteins were considered deﬁcient when
their activity was <50% of their normal functionality.
2.3. Statistical Analysis. The sample size was calculated using
the software tama˜ no de la muestra (versi´ on 1.1) [32]. The
allele and genotype frequencies were compared between
patients and controls with a Mantel and Haenzel’s chi-square
test and one-tail analysis using SPSS 15.0 [33]. The ORs were
calculated with 95% Cornﬁeld’s conﬁdence intervals (CIs)
using Epi 6 Stat Calc [34].
3. Results
Demographics of the women from the case and the control
groupsareshowninTable 1.In93casesand206controls,the
frequency of thrombophilia-associated SNPs (as shown in
Table 2) for both FV Leiden and FII G20210A heterozygous
carriers was one patient and one control (1.1% versus 0.5%,
resp.; OR 2.25; 95% CI, 0–83). Homozygous carriers of the
MTHFR 677T allele were detected in 12 patients and 30
controls (12.9% versus 14.9%, resp.; OR 0.85; 95% CI, 0.4–
1.8). APC resistance was found in 5 of 87 patients versus 8 of
187 controls (5.7% versus 4.3%, resp.; OR 1.36; 95% CI, 0.4–
4.8)ofwhichonlyonewomenineachgroupwasattributable
to FV Leiden. Additionally, none of the patients and only two
of the controls had <50% AT activity (0 versus 1%, resp.;
OR 0; 95%, CI 0–9.2), and 2 of 91 patients versus 3 of 195
controls showed <50% in PC activity (2.2 versus 1.5%, resp.;
OR 1.44; 95% CI, 0.2–10.8), as shown in Table 3. Since the
determinations of PS levels were nonreproducible in stored
samples, these measurements were excluded from analysis in
this study. No association was observed between recurrent
pregnancy loss and inherited thrombophilia by either SNP
genotypes(FVLeiden,FIIG20210A,andMTHFRC677T)orThrombosis 3
Table 2: Genotype frequency of thrombophilias.
SNP Genotype Cases, n (%) Controls, n (%) OR (CI 95%)
FV Leiden
GG (normal) 92 (98.9%) 205 (99.5%) 0.4 (0–16.44)
GA 1 (1.1%) 1 (0.5%) 2.2 (0–83)
AA 0 0 ND
Total 93 (100%) 206 (100%)
FII G20210A
GG (normal) 92 (98.9%) 205 (99.5%) 0.4 (0–16.4)
GA 1 (1.1%) 1 (0.5%) 2.2 (0–83)
AA 0 0 ND
Total 93 (100%) 206 (100%)
MTHFR C677T
CC (normal) 38 (40.9%) 93 (45.1%) 0.8 (0.5–1.4)
CT 43 (46.2%) 83 (40%) 1.3 (0.8–2.1)
TT 12 (12.9%) 30 (14.9%) 0.8 (0.4–1.8)
Total 93 (100%) 206 (100%)
SNP: single nucleotide polymorphism; n: number of women; OR: odds ratio; CI 95%: Cornﬁeld’s 95% conﬁdence interval for the OR; ND: not determined
(0% frequency); FV: factor V; FII: prothrombin; MTHFR: methylenetetrahydrofolate reductase.
Table 3: Frequency of antithrombin deﬁciency, protein C deﬁciency, and activated protein C resistance.
Alteration Cases, n (%) Controls, n (%) OR (CI 95%)∗
AT deﬁciency (<50%) 0 2 (1%) 0 (0–9.2)
PC deﬁciency (<50%) 2 (2.2%) 3 (1.5%) 1.44 (0.2–10.8)
APC resistance 5 (5.7%) 8 (4.3%) 1.36 (0.4–4.8)
APC resistance with FV Leiden 1 (20%) 1 (12.5%) 1.75 (0–93)
APC resistance without FV Leiden 4 (80%) 7 (87.5%) N/A
n: number of women; OR: odds ratio; CI 95%: Cornﬁeld’s 95% conﬁdence interval for the OR; AT: antithrombin; PC: protein C; APC: activated protein C.
N/A: not applicable.
functional phenotypes (APC resistance, PC deﬁciency, and
AT deﬁciency).
4. Discussion
Thepresentstudyistheﬁrsttoreportthefrequencyofinher-
ited thrombophilia (thrombophilic polymorphisms and
functional tests) in a group of Colombian patients with
recurrent pregnancy loss. Thrombophilia-associated SNPs
such FV Leiden and FII G20210A were very low in both
patientsandcontrols,andalthoughthefrequencyofMTHFR
C677T SNPs was high in the patients, diﬀerences were not
signiﬁcant. Other inherited thrombophilias such as PC and
AT deﬁciency are not commonly found in patients who
had already experienced recurrent pregnancy loss. Only
three patients with PC deﬁciency and no patients with AT
deﬁciency were found among 93 cases. Overall, we found
a low frequency of inherited thrombophilia in our patient
population unlike Caucasian populations; therefore, it is un-
likely that the thrombophilic alterations studied play a role
in the pathogenesis of recurrent pregnancy loss in this Latin
American population.
T h el o wf r e q u e n c yo fF VL e i d e ni no u rs t u d ya g r e e sw i t h
two previous reports on the Colombian population. Cama-
cho Vanegas et al. tested 150 healthy individuals from Bogota
(30–50 years old) using PCR-RFLP and found no evidence of
FVLeiden[35];however,theallelicfrequencyoftheMTHFR
C677T SNP was 0.487, one of highest reported in the liter-
ature (70/150 heterozygous CT and 38/150 homozygous
TT) [35]. The other study was performed by Varela et al.
and used PCR-sequence speciﬁc oligonucleotide probes in
495 Colombian blood donors from banks in four cities,
reporting a prevalence of FV Leiden of 1.9% (7/370) in indi-
viduals from Bogota, while it was 0% in 125 individuals
fromtheotherthreecities(Medell´ ın,Bucaramanga,andBar-
ranquilla)[36]. In addition, the presence of inherited throm-
bophiliain100Colombianpatientswithdeepvenousthrom-
bosis and in a control group (n = 114) was evaluated with
the following results in patients versus controls: 10% versus
0.9% were heterozygous for FV Leiden, 3% versus 0% were
heterozygous for FII G20210A (one patient was homozy-
gous), 24% versus 19.3% were homozygous for MTHFR
677T, and 25.2% versus 5.3% had APC resistance (these
thrombophilias reached statistical signiﬁcance, except for
the MTHFR polymorphisms) [37]. During this research,
the ﬁrst homozygous family for the G20210A prothrombin
polymorphism reported in Latin America, although only
some carriers developed venous thrombosis [38].
The FV Leiden, as genetic factor involved in the etiology
of thrombosis, has motivated research of this abnormality
as a risk factor for recurrent pregnancy loss, as reviewed by
Krabbendam et al. [39]; however, this association has not
been easy to conﬁrm in multiple studies, making it necessary
to reevaluate the experimental design and population size.
For example, Nurk et al. [40] evaluated FV Leiden in4 Thrombosis
5874 women and found that this polymorphism is a risk
factor for pregnancy complications and correlated with ad-
verse outcomes. On the other hand, some researchers have
shown no association between inherited thrombophilia and
recurrent pregnancy loss [41–45], possibly because either the
only evaluated SNP was MTHFR C677T [43, 44] or the sam-
ple sizes were small, that is, 40 patients and 20 controls [42]
and55womenwithrecurrentpregnancylossand50controls
[41]. Additionally, in a Malasyan population, the identiﬁca-
tion of FV Leiden and FII G20210A in women with recurrent
pregnancy loss was also low [46].
Our results are in contrast with previous recurrent preg-
nancy loss studies in Latin American populations. Brazilian
women carrying FV Leiden had a 4.9 times higher risk of
recurrent pregnancy loss than noncarriers [9], and women
heterozygous for FV Leiden from Uruguay had a 5 times
higher risk of recurrent pregnancy loss than noncarriers
(CI 95%, 1.5–21) [47]. Therefore, our study highlights spe-
cial genetic characteristics in this triethnic population from
Colombia compared to populations with a higher percentage
of Caucasians [23, 24]. Our results conﬁrm the diﬀerences
in the genetic background between Caucasian and non-Cau-
casian populations, in one extreme populations such as the
Japanese that virtually lacks FV Leiden carriers [48]a n d
somewhere in the spectrum of thrombophilia frequency,
our triethnic population with low frequency but identiﬁable
thrombophilia-associated SNPs. These results provide evi-
dence of how a genetic component such as polymorphisms
in genes associated with thrombosis and its interaction with
diverse environmental factors such as food, geographical
location, medical resources, public health, and the age of the
woman could lead to variable manifestations of complex
diseases such as recurrent pregnancy loss.
In the current study, the wide conﬁdence intervals sug-
gest that the estimated sample size of 300 individuals was
insuﬃcient to detectdiﬀerences between patients with recur-
rent pregnancy loss and control women for whom the power
of the study decreased from an estimated 80% to 30% for
detections of an OR of 2.0 with a frequency of 0.5% for FV
Leiden in the controls. Nevertheless, our results are valuable
because they conﬁrm that the frequency of these inherited
thrombophilias in our populations is low; therefore, we be-
lieve that there is no justiﬁcation to recommend testing in-
herited thrombophilias in the initial evaluation of patients
with recurrent pregnancy loss. To detect an association bet-
ween thrombophilias and recurrent pregnancy loss, it would
benecessarytoincreaseconsiderablythesamplesizebutwith
unlikely clinical signiﬁcance.
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